Review, Early Access, 2024

Biomarker-guided drug development provides value for patients, payers and drug developers: lessons learned from 25 years in the biomarker industry

BIOMARKERS, ISSN 1354-750X, 10.1080/1354750X.2024.2342016

Contributors

Reese-Petersen, Alexander 0000-0001-9044-2475 (Corresponding author) [1] Breisnes, H. W. [1] Gabor, Daniel [1] Ronnow, Sarah R. [1] Manoel, Bruna 0009-0003-3867-4289 [1] Bajaj, Mayuur [1] Von Arenstorff, Claus S. [1] Aighobahi, Elijah [1] Vestermark, Rune [1] Karsdal, Morten A. [1]

Affiliations

  1. [1] Nordic Biosci AS, Res & Dev, Herlev, Denmark
    2. [NORA names: Denmark; Europe, EU; Nordic; OECD]

Abstract

Abstract not displayed. As this article is not marked as Open Access, it is unclear if we are allowed to show the abstract. Please use the link in the sidebar to view the data provider version of the article including abstract.

Keywords

Biomarkers, clinical development, drug development

Data Provider: Clarivate

LINKS
-

Matching Records in NORA

SUBJECTS
+

METRICS
+